On March 27, 2019, Smith, Eric L.; Harrington, Kim; Staehr, Mette; Masakayan, Reed; Jones, Jon; Long, Thomas J.; Ng, Khong Y.; Ghoddusi, Maj; Purdon, Terence J.; Wang, Xiuyan; Do, Trevor; Pham, Minh Thu; Brown, Jessica M.; De Larrea, Carlos Fernandez; Olson, Eric; Peguero, Elizabeth; Wang, Pei; Liu, Hong; Xu, Yiyang; Garrett-Thomson, Sarah C.; Almo, Steven C.; Wendel, Hans-Guo; Riviere, Isabelle; Liu, Cheng; Sather, Blythe; Brentjens, Renier J. published an article.Application of 55779-48-1 The title of the article was GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. And the article contained the following:
The orphan G protein-coupled receptor, class C group 5 member D (GPRC5D), normally expressed only in the hair follicle, was previously identified as expressed by mRNA in marrow aspirates from patients with MM, but confirmation of protein expression remained elusive. Using quant. immunofluorescence, we determined that GPRC5D protein is expressed on CD138+ MM cells from primary marrow samples with a distribution that was similar to, but independent of, BCMA. Panning a human B cell-derived phage display library identified seven GPRC5D-specific single-chain variable fragments (scFvs). Incorporation of these into multiple CAR formats yielded 42 different constructs, which were screened for antigen-specific and antigen-independent (tonic) signaling using a Nur77-based reporter system. Nur77 reporter screen results were confirmed in vivo using a marrow-tropic MM xenograft in mice. CAR T cells incorporating GPRC5D-targeted scFv clone 109 eradicated MM and enabled long-term survival, including in a BCMA antigen escape model. GPRC5D(109) is specific for GPRC5D and resulted in MM cell line and primary MM cytotoxicity, cytokine release, and in vivo activity comparable to anti-BCMA CAR T cells. Murine and cynomolgus cross-reactive CAR T cells did not cause alopecia or other signs of GPRC5D-mediated toxicity in these species. Thus, GPRC5D(109) CAR T cell therapy shows potential for the treatment of advanced MM irresp. of previous BCMA-targeted therapy. The experimental process involved the reaction of 8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one(cas: 55779-48-1).Application of 55779-48-1
The Article related to multiple myeloma chimeric antigen receptor t cell gprc5d, Immunochemistry: Other (Immunity, Immune Suppression, Tolerance, etc.) and other aspects.Application of 55779-48-1